VALIANTLAB
Valiant Laboratories Limited
Paracetamol and Acetic Anhydride manufacturer
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
valiantlabs.in(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Valiant Laboratories manufactures paracetamol, a pharmaceutical active ingredient, at its Tarapur plant and sells almost all of it within India.
Company snapshot
96thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Debt-to-equity of 0.14x — the company is largely funded by its own money, not borrowed funds.
- ✗Net margin is negative — the company is spending more than it earns right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 Cr | 41 Cr | 31 Cr | 19 Cr | 21 Cr | 35 Cr | 58 Cr | 47 Cr | 46 Cr | 52 Cr | 92 Cr | 115 Cr |
| Operating expenses (approx.) | 61 Cr | 47 Cr | 35 Cr | 21 Cr | 28 Cr | 35 Cr | 54 Cr | 44 Cr | 46 Cr | 53 Cr | 87 Cr | 86 Cr |
| EBITDA | -1 Cr | -6 Cr | -5 Cr | -2 Cr | -7 Cr | 0.62 Cr | 4 Cr | 2 Cr | 0.08 Cr | -0.89 Cr | 5 Cr | 29 Cr |
| OPM % | -2.3% | -15.6% | -14.8% | -12.6% | -31.4% | 1.8% | 6.6% | 5.1% | 0.2% | -1.7% | 5.2% | 25.4% |
| Other income | 3 Cr | 2 Cr | 3 Cr | 3 Cr | 3 Cr | 2 Cr | -2 Cr | 0.66 Cr | 0.87 Cr | 0.63 Cr | 0.17 Cr | 0.86 Cr |
| Interest | 0.02 Cr | 0.02 Cr | 0.02 Cr | 0.05 Cr | 0.0061 Cr | 0.06 Cr | 0.05 Cr | 0.07 Cr | 0.14 Cr | 0.68 Cr | 1 Cr | 1 Cr |
| Depreciation | 0.49 Cr | 0.49 Cr | 0.52 Cr | 0.53 Cr | 0.52 Cr | 0.52 Cr | 0.52 Cr | 0.53 Cr | 0.53 Cr | 2 Cr | 3 Cr | 3 Cr |
| Profit before tax | 1 Cr | -5 Cr | -3 Cr | -0.16 Cr | -4 Cr | 2 Cr | 0.94 Cr | 2 Cr | 0.28 Cr | -3 Cr | 1 Cr | 26 Cr |
| Tax % | 25.4% | 30.6% | 51.7% | -214.4% | -21.3% | -44.9% | 25.1% | 25.6% | 27.6% | -136.0% | -68.0% | 19.4% |
| Net profit | 0.79 Cr | -4 Cr | -1 Cr | -0.51 Cr | -5 Cr | 2 Cr | 0.70 Cr | 2 Cr | 0.20 Cr | -7 Cr | 2 Cr | 21 Cr |
| EPS (₹) | ₹0.24 | ₹-0.81 | ₹-0.33 | ₹-0.12 | ₹-1.09 | ₹0.54 | ₹0.16 | ₹0.42 | ₹0.04 | ₹-1.30 | ₹0.32 | ₹3.89 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 182 Cr | 133 Cr | 237 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 190 Cr | 138 Cr | 231 Cr | Sign in free for the trailing twelve months |
| EBITDA | -8 Cr | -5 Cr | 6 Cr | Sign in free for the trailing twelve months |
| OPM % | -4.6% | -3.5% | 2.7% | Sign in free for the trailing twelve months |
| Other income | 10 Cr | 5 Cr | 2 Cr | Sign in free for the trailing twelve months |
| Interest | 0.08 Cr | 0.18 Cr | 2 Cr | Sign in free for the trailing twelve months |
| Depreciation | 2 Cr | 2 Cr | 6 Cr | Sign in free for the trailing twelve months |
| Profit before tax | -0.77 Cr | -2 Cr | 0.77 Cr | Sign in free for the trailing twelve months |
| Tax % | 141.5% | -45.5% | 525.4% | Sign in free for the trailing twelve months |
| Net profit | 0.32 Cr | -2 Cr | -3 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹0.13 | ₹-0.51 | ₹-0.51 | Sign in free for the trailing twelve months |
| Dividend payout % | 0.0% | — | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 43 Cr | 43 Cr | 54 Cr |
| Reserves | 193 Cr | 191 Cr | 257 Cr |
| Borrowings | 76 Cr | 121 Cr | 45 Cr |
| Other liabilities | 30 Cr | 45 Cr | 108 Cr |
| Total liabilities | 343 Cr | 401 Cr | 464 Cr |
| Fixed assets (net) | 50 Cr | 48 Cr | 227 Cr |
| CWIP | 43 Cr | 156 Cr | 6 Cr |
| Investments | 38 Cr | 0 Cr | 26 Cr |
| Loans & advances | 0.03 Cr | 0.06 Cr | 0.04 Cr |
| Inventories | 10 Cr | 4 Cr | 45 Cr |
| Trade receivables | 46 Cr | 72 Cr | 94 Cr |
| Cash & bank | 12 Cr | 5 Cr | 4 Cr |
| Other assets | 145 Cr | 116 Cr | 62 Cr |
| Total assets | 343 Cr | 401 Cr | 464 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 2 Cr | 1 Cr | -10 Cr |
| Cash from investing | -144 Cr | -53 Cr | 7 Cr |
| Cash from financing | 152 Cr | 45 Cr | 2 Cr |
| Net cash flow | 10 Cr | -7 Cr | -1 Cr |
| Free cash flow (OCF − Capex) | -44 Cr | -113 Cr | -45 Cr |
Ratios
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | -0.2% | -0.4% | 0.8% |
| ROE % | 0.1% | -0.9% | -1.1% |
| Debtor days | 92 | 197 | 143 |
| Inventory days | 22 | 13 | 87 |
| Days payable | 56 | 132 | 179 |
| Cash conversion cycle | 57 | 78 | 51 |
| OCF / EBITDA % | — | — | n.m. |
| Debt / equity | 0.32 | 0.52 | 0.14 |
| Current ratio | 7.76 | 3.23 | 1.91 |
| Net debt / EBITDA | — | — | 6.48 |